External Resources

What is CAR T-cell therapy for lymphoma?

• CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers

When to consider CAR T-cell therapy? 

• CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies
• CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers 

FDA-approved lymphoma CAR T-cell therapies

• Yescarta Prescribing Information
• Breyanzi Prescribing Information
• Kymriah Prescribing Information
• Tecartus Prescribing Information
• Receiving YESCARTA
• How will I receive BREYANZI?
• What to Expect With KYMRIAH
• Boom-Boom Radiation as Bridging Therapy Prior to CAR-T for DLBCL
• Optimizing bridging therapy before CAR-T in patients with lymphoma
• A promising step for high-risk FL
• Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
• Kymriah Efficacy
• Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
• Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Side effect management of CAR T-cell therapy for lymphoma

• Cytokine release syndrome
• Grading of cytokine release syndrome associated with the CAR T cell therapy
• Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
• CAR T-Cell Grading and Management: ICANS
• In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
• Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
• Managing Fatigue, Anemia, and GI Side Effects with Nutrition
• Cytopenia
• Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
• Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies
• Immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurologic toxicities of CAR-T cell and related therapies
• Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations 
• Potential Side Effects of CAR T-cell Therapy: Symptoms & Treatment
• New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
• Nausea and vomiting

A look ahead: The future of lymphoma CAR T-cell therapy

• Minimally modified off-the-shelf allogeneic CAR T cells
• Allogeneic off-the-shelf CAR T-cell therapy
• The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma
• AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’

Caregiver role in lymphoma CAR-T

• The Role of the Caregiver
• Caregiving for CAR T Cell Therapy
• Let’s Chat CAR T: For Caregivers
• Let’s Chat CAR T: Find Support
• Overcoming Caregiver Barriers in CAR T-Cell Therapy Referrals

Communicating with your healthcare team

• Transferring Clinics: It Begins With You